COVID-associated arthritis

  • 文章类型: Systematic Review
    目标:自2020年冠状病毒爆发成为全球卫生紧急情况以来,各种基于免疫的影响,如炎性关节炎(IA),已被记录下来。这项研究旨在确定COVID-19严重程度在COVID后关节炎中的作用。
    方法:我们通过检索数据库,系统回顾了95例严重和非严重COVID-19感染后出现关节炎的患者,包括PubMed,Scopus,和EMBASE。我们使用术语“COVID相关性关节炎”,因为没有明确的诊断方法来分类COVID-19感染后的关节炎,诊断的关节炎类型是基于作者的观点。
    结果:在评估了两个严重和非严重COVID-19感染患者组之间的数据后,结果表明,COVID-19的严重程度可能会影响IA的关节受累方式。在这两组中,联合治疗,包括口服非甾体抗炎药与不同类型的皮质类固醇,是最常见的治疗方法。此外,重症COVID-19组的平均年龄和合并症发生率较高.即使严重COVID-19组的患者出现了更严重的COVID-19症状,他们经历了较轻的关节炎,预后较好,延迟发作较多,需要较少的积极治疗.
    结论:我们得出结论,COVID-19严重程度与关节炎严重程度之间可能存在反比关系,可能是由于严重COVID-19患者接受免疫抑制剂治疗后免疫力较弱。
    Since the coronavirus outbreak became a global health emergency in 2020, various immune-based effects, such as inflammatory arthritis (IA), have been recorded. This study aimed to determine the role of COVID-19 severity on post-COVID arthritis.
    We systematically reviewed 95 patients who developed arthritis after severe and non-severe COVID-19 infection by searching the databases, including PubMed, SCOPUS, and EMBASE. We used the term \"COVID-associated arthritis\" because there was no definite diagnostic method for classifying arthritides after COVID-19 infection, and the diagnosed arthritis types were based on the authors\' viewpoints.
    After evaluating the data between the two severe and non-severe COVID-19-infected groups of patients, the results showed that the COVID-19 severity may affect the pattern of joint involvement in IA. In both groups, combination therapy, including oral nonsteroidal anti-inflammatory drugs with different types of corticosteroids, was the most common treatment. In addition, the mean age and comorbidities rate was higher in the severe COVID-19 group. Even though the patients in the severe COVID-19 group developed more serious COVID-19 symptoms, they experienced milder arthritis with better outcomes and more delayed onsets that required less aggressive therapy.
    We conclude that there may be an inverse relationship between COVID-19 severity and arthritis severity, possibly due to weaker immunity conditions following immunosuppressant treatments in patients with severe COVID-19.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

公众号